Scarica l'app Stockscreener
61.00
3.51%
-2.59
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$63.59
Aprire:
$63.49
Volume 24 ore:
242.18K
Relative Volume:
0.11
Capitalizzazione di mercato:
$7.32B
Reddito:
$18.47M
Utile/perdita netta:
$-589.53M
Rapporto P/E:
-11.60
EPS:
-5.26
Flusso di cassa netto:
$-399.80M
1 W Prestazione:
+1.96%
1M Prestazione:
+7.71%
6M Prestazione:
+64.28%
1 anno Prestazione:
+18.41%
Intervallo 1D:
$61.14
$63.96
Intervallo di 1 settimana:
$59.52
$64.13
Portata 52W:
$29.31
$64.13
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta CYTK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
61.14 | 7.61B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.50 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
638.23 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.90 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.39 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.24 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | Raymond James | Mkt Perform |
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Nisa Investment Advisors LLC Decreases Holdings in Cytokinetics, Incorporated $CYTK - Defense World
The Gross Law Firm Notifies Cytokinetics, Incorporated Investors of a Class Action Lawsuit and Upcoming DeadlineCYTK - Morningstar
35,600 Shares in Cytokinetics, Incorporated $CYTK Purchased by Zweig DiMenna Associates LLC - MarketBeat
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Key metrics from Cytokinetics Incorporated’s quarterly dataEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
How Cytokinetics Incorporated stock benefits from strong dollarJuly 2025 Gainers & Weekly Breakout Opportunity Watchlist - newser.com
Does Cytokinetics Incorporated qualify in momentum factor screening2025 Market Sentiment & Fast Moving Stock Trade Plans - newser.com
Key facts: Cytokinetics' stock drops 12.98% after FDA delay; lawsuit filed - TradingView
What MACD and RSI say about Cytokinetics Incorporated2025 Institutional Moves & Weekly High Potential Alerts - newser.com
Cytokinetics Incorporated recovery potential after sell off2025 Big Picture & Real-Time Volume Surge Alerts - newser.com
Pinnacle Associates Ltd. Reduces Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Why analysts remain bullish on Cytokinetics Incorporated stockMarket Movers & AI Enhanced Execution Alerts - newser.com
Is Cytokinetics Incorporated stock positioned for long term growthPortfolio Value Report & Expert Approved Momentum Ideas - newser.com
Key facts: Cytokinetics shares fall 12.98% amid FDA delay; lawsuit filed - TradingView
Cytokinetics (NASDAQ:CYTK) Reaches New 1-Year HighHere's Why - MarketBeat
Robert Blum Sells 5,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, - GlobeNewswire
Cytokinetics, Inc. Hits New 52-Week High at USD 64.13 - Markets Mojo
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - MarketScreener
Cytokinetics Announces Upcoming Late Breaking Science Presentations on Aficamten at Major Cardiovascular Conferences - Quiver Quantitative
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical ... - nrtoday.com
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 - Yahoo Finance
Can Cytokinetics Incorporated (KK3A) stock test all time highs2025 Stock Rankings & Community Consensus Stock Picks - newser.com
How sentiment analysis helps forecast Cytokinetics IncorporatedMarket Performance Recap & Weekly Stock Performance Updates - newser.com
Analyzing recovery setups for Cytokinetics Incorporated investorsJuly 2025 Market Mood & Daily Oversold Stock Bounce Ideas - newser.com
What dividend safety score for Cytokinetics Incorporated stock2025 Volume Leaders & Smart Allocation Stock Tips - newser.com
Applying Elliott Wave Theory to Cytokinetics IncorporatedJuly 2025 Catalysts & Long-Term Capital Growth Strategies - newser.com
Is Cytokinetics Incorporated stock a smart buy before Fed meetingJuly 2025 Short Interest & Fast Moving Stock Watchlists - newser.com
How to track smart money flows in Cytokinetics IncorporatedQuarterly Portfolio Report & AI Enhanced Execution Alerts - newser.com
Blum, Cytokinetics CEO, sells $314k in stock By Investing.com - Investing.com Australia
Cytokinetics stock hits 52-week high at 63.87 USD By Investing.com - Investing.com Canada
Investors SueWallSt as Cytokinetics, Incorporated Faces Securities Fraud Allegations - Nasdaq
Blum, Cytokinetics CEO, sells $314k in stock - Investing.com
Cytokinetics (CYTK): Exploring Valuation After Recent Share Price Momentum and Growth Narrative - Yahoo Finance
Cytokinetics, Incorporated Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law ... - Caledonian Record
Cytokinetics, Incorporated Securities Fraud Class Action - GlobeNewswire
Deadline Alert: Cytokinetics, Incorporated (CYTK) - GlobeNewswire
Deadline Alert: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Cytokinetics stock hits 52-week high at 63.87 USD - Investing.com
Cytokinetics (CYTK) to Release Earnings on Wednesday - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Bought by State of New Jersey Common Pension Fund D - MarketBeat
Cytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, Incorporated - GlobeNewswire Inc.
CYTOKINETICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urgently Reminds CYTK ... - Bluefield Daily Telegraph
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit - Barchart.com
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FinancialContent
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - MarketScreener
Earnings Preview: Cytokinetics (CYTK) Q3 Earnings Expected to Decline - Yahoo Finance
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Cytokinetics Shareholder Alert By Former Louisiana Attorney - GlobeNewswire
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.21%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):